



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2014

**New Onset of Kaposi Sarcoma in a Human Immunodeficiency
Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment,
Sustained Viral Suppression, and Immune Restoration**

von Braun, A ; Braun, D L ; Kamarachev, J ; Gunthard, H F

Abstract: This is a rare case of new onset Kaposi sarcoma in a man infected with human immunodeficiency virus (HIV) and receiving antiretroviral treatment since primary HIV infection, with normal CD4+ cell count and suppressed viral load. The presentation questions the general understanding of Kaposi sarcoma as an acquired immune deficiency syndrome-defining disease occurring predominantly in severely immunocompromised patients infected with HIV.

DOI: <https://doi.org/10.1093/ofid/ofu005>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-106642>

Journal Article

Accepted Version

Originally published at:

von Braun, A; Braun, D L; Kamarachev, J; Gunthard, H F (2014). New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment, Sustained Viral Suppression, and Immune Restoration. Open Forum Infectious Diseases, 1(1):ofu005.

DOI: <https://doi.org/10.1093/ofid/ofu005>

New onset of Kaposi sarcoma in an HIV-1-infected homosexual man, despite early antiretroviral treatment, sustained viral suppression, and immune restoration

Amrei von Braun^{1,*}, Dominique L. Braun^{1,*}, Jivko Kamarachev², Huldrych F. Günthard¹

¹Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

²Division of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

*These authors contributed to the manuscript equally.

Corresponding author: Amrei von Braun, University Hospital Zurich, Division of Infectious Diseases, and Hospital Epidemiology, Raemistrasse 100, CH-8091 Zurich, Switzerland, Phone (direct) +41 44 255 91 79, Fax: +41 44 255 44 99, Amrei.vonbraun@usz.ch

Alternate corresponding author: Dominique L. Braun, MD, University Hospital Zurich, Division of Infectious Diseases, and Hospital Epidemiology, Raemistrasse 100, CH-8091 Zurich, Switzerland, Phone (direct) +41 44 255 91 96, Fax: +41 44 255 44 99, dominique.braun@usz.ch

Abstract

This is a rare case of new onset Kaposi sarcoma in an HIV-infected man on antiretroviral treatment since primary HIV infection, with normal CD4⁺ cell count and suppressed viral load. The presentation questions the general understanding of Kaposi sarcoma as an AIDS-defining disease occurring predominantly in severely immunocompromised HIV-infected patients.

Case Report

A 45 year old HIV-infected Caucasian man presented with an acute onset of a dark patchy skin lesion on his left foot (figure 1A) and a smaller dark papule on his penis (figure 1B). The painless lesions had developed within a few days. He otherwise felt healthy and denied further symptoms. He had neither engaged in risky sexual behavior nor had he traveled recently. On physical examination no other physical abnormalities were seen.

The patient is a MSM (men who have sex with men) and was diagnosed with primary HIV-1 infection in April 2009. At that time, he presented with symptoms of an acute retroviral syndrome, had a negative HIV screening test in November 2008 and the HIV Western Blot was positive for 3 of 5 bands in the presence of a detectable p24 antigen. His baseline CD4⁺ cell count was 512/ul with a viral load of 4 million HIV-1 RNA copies/ml of plasma. He was immediately started on early antiretroviral treatment (ART) consisting of ritonavir-boosted darunavir combined with tenofovir and emtricitabine as part of the Zurich Primary HIV Infection Study¹. Under antiretroviral therapy the patient's CD4⁺ cell count remained stably above 500/ul until today (range: 606/ul – 1002/ul, 29%-34%). His viral load has been consistently undetectable (< 20 HIV-1 RNA copies/ml of plasma) for more than four years.

As HIV-associated Kaposi sarcoma (KS) was suspected, skin biopsy of the lesion on his left foot was performed. The histology showed a dermal tumor consisting of spindle cells with some irregular vessel lumina formation, as well as plasma cells and erythrocyte extravasates in the tumoral stroma yielding the diagnosis of KS (Figure 2A). Immunohistochemistry proved the lymph vessel origin of the tumor by showing positivity for the lymph vessel marker d2-40. Further HHV-8 immunochemistry staining was positive in the spindle cells (Figure 2B), thus confirming the histological diagnosis.

Based on its clinical aspect, the genital lesion was considered to be KS as well. Laboratory results showed normal C-reactive protein, blood count, liver and kidney function. Syphilis was ruled out by serology. The HIV-1 viral load was fully suppressed and his CD4⁺ cell count measured 620/ul (30%).

Differentiation of T-cells showed increased expression of immune activation markers such as increased CD4/38 of 25/ul (normal: 4-22/ul) and CD8 HLA-DR of 135/ul (normal: 6-108/ul). Human Herpes Virus 8 (HHV-8) serologies and PCR were performed retrospectively from a blood-sample collected in April 2009 when the patient was first diagnosed with primary HIV-1 infection. The

immunofluorescence assay revealed IgG antibodies against latent and lytic antigens in both samples, while IgM was negative, reflecting former HHV-8 infection. The HHV-8 PCR was negative in April 2009 but showed 593 copies/ml of plasma at the onset of KS. To screen for possible further organ involvement gastroesophagoduodenoscopy and colonoscopy were done, both showing no visceral lesions. A chest X-ray was normal as well. The patient's current ART consisting of ritonavir-boosted darunavir combined with tenofovir and emtricitabine was continued. After visceral KS had been ruled out, the lesion on the left foot was treated locally with cryotherapy. The genital lesion disappeared spontaneously after 8 weeks and repeat HHV-8 PCR was negative. The patient continues to be seen at our hospital regularly and is doing well at 6 months. The lesion on his right foot has healed completely. No further lesions have appeared in the meantime. He remains stably on ART with suppressed viral load and high CD4⁺ cell count.

KS is considered an AIDS-defining neoplastic disease in HIV-infected patients¹ and is caused by HHV-8. The vascular nodules of the angioproliferative tumor appear on the skin, mucous membranes and rarely in visceral organs (especially GI tract, lungs). Lymph node involvement is common. Clinical findings range from single or multiple skin lesions as seen in our case to vastly disseminated disease. Diagnosis is based on the clinical aspect of the lesion and the biopsy, which histologically shows a proliferation of spindle cells and endothelial cells, extravasation of red blood cells and hemosiderin-laden macrophages². The development of KS in HIV-infected patients has historically been associated with low CD4⁺ cell counts (usually <200/ul) and the absence of ART. While KS was common in HIV-infected patients in the 1980s and 1990s, occurring in up to 67% of patients diagnosed with HIV², today it is rarely seen in countries with widespread distribution of effective ART³. Most patients who develop KS while on ART began treatment with low CD4⁺ cell counts and develop KS within the first 6 months since initiation of ART⁴. A retrospective study by Daly et al aimed to investigate the characteristics of HIV-infected patients with CD4⁺ cell counts of >300 cells/ul and the presence of histologically confirmed KS⁵. Of the 23 cases described, seven (30%) presented with new onset KS while showing CD4⁺ cell counts >300/ul. All of the cases were MSM with a median age of 39 years (range 26-66 years) and only two of the patients were on ART at the time of diagnosis. This last fact prompts the authors to rule out immune reconstitution through ART as the sole cause of new onset KS in patients with high CD4⁺ cell counts. Crum-Cianflone et al.

evaluated longitudinal rates of Kaposi sarcoma and trends in CD4⁺ cell counts during the HIV epidemic (1985 – 2008)⁶. The group was able to demonstrate an increase of the proportion of KS cases in patients with higher CD4⁺ cell counts (> 350/μl) in a setting with widespread access to ART, which further highlighted the importance that clinicians should be aware of the occurrence of Kaposi's sarcoma despite robust CD4⁺ cell counts.

HHV-8 also referred to as Kaposi sarcoma-associated Herpes virus (KSHV) was identified in 1994 as the etiological agent of KS⁷. HHV-8 infection is necessary but not sufficient for the development of KS. HIV coinfection and immunosuppression significantly increase an HHV-8 seropositive patient's risk of developing a KS⁸. As other Herpes viruses it is transmitted through close person-to-person contact and establishes persistent infection. We were able to show a sudden and transient HHV-8 viremia in our patient at the time of onset of KS. Since the blood sample collected in 2009 already revealed seropositivity, a primary HHV-8 infection could be ruled out at the onset of disease. Sullivan et al. found a HHV-8 seropositivity rate of 69–75% in MSM in Switzerland without KS, suggesting widespread exposure to this virus in Swiss MSM⁹. We conclude that viral reactivation of unknown origin most likely contributed to the development of new onset KS in our patient. A further possible explanation for the patient's transient HHV-8 viremia could be superinfection with a different HHV-8 strain. Beyari et al were able to demonstrate multiple HHV-8 infection in a study population from Malawi¹⁰. Whether multiple HHV-8 carriage reflects simultaneous coinfection with more than one strain or superinfection remains unclear though. Most likely both options are possible.

So far, defined staging guidelines for KS do not exist. Most management recommendations by clinical HIV societies do not include routine staging investigations such as CT-scan, bronchoscopy or GI endoscopy in the absence of symptoms¹¹. We decided to perform a chest X-ray as well as upper and lower GI tract endoscopy before initiating a treatment strategy since single skin lesions can be treated locally.

Independently of any other factor all HIV-infected patients diagnosed with KS should receive ART⁸.

Effective antiretroviral regimens reduce the incidence of AIDS-related KS and are associated with histological regression of existing lesions in most cases. Limited local disease may be treated with a variety of therapies depending on size and location including cryotherapy, laser therapy, radiation and intralesional chemotherapy (e.g. vinblastine). Systemic therapies for disseminated disease approved

by the FDA include two liposomal anthracyclines (doxorubicin and daunorubicin) and the taxane paclitaxel.

The development of KS in HIV-infected patients with high CD4⁺ cell count – as seen in our case - is rare. While theoretically KS may occur at any stage of HIV infection, to our knowledge so far merely a few case reports of KS in patients with high CD4⁺ cell count were published¹². Our case is the first one published on the occurrence of KS in a patient effectively treated with early ART since diagnosis of primary HIV infection. What triggers the development of KS in patients under successful ART with formally normal immune function is still unknown. Increased immune activation may be a possible cofactor. As mentioned above, laboratory investigations found signs of immune activation in our patient. However, whether KS itself leads to immune activation or *vice versa* remains unclear.

The answer to the question why some individuals are able to successfully control persistent HHV-8 infection and thereby prevent the onset of KS while others are not most likely lies in the HHV-8 specific immune responses, which are still poorly understood¹³. Lambert M. et al compared the HHV-8 specific CD8⁺ T-cell responses in transplant recipients and HIV-infected patients with and without KS. The patients who did not develop KS clearly had more frequent anti-HHV-8 T-cell responses. Since the cellular response to Cytomegalovirus, a further latent virus, was similar in both patient groups, the author's findings do not seem to reflect global CD8⁺ dysfunction¹⁴. The observations show lower HHV-8 specific CD8⁺ T cell response and lower response to HHV-8 specific antigens in patients progressing to KS. A study published by the Swiss HIV Cohort Study was able to show that the humoral immune response to HHV-8 increases after 24 months of highly active antiretroviral treatment (HAART), even in MSM without KS⁹. This humoral immune response together with changes in cellular immunity explains the protection against KS offered by HAART. The occurrence of KS in a patient started on HAART during primary HIV infection is even more remarkable since initiation of HAART at a very early stage of infection is associated with preserved immune function¹⁴. One could hypothesize that this fact should have contributed to a sufficient control of latent HHV-8 infection.

Luckily, KS has become a rare malignancy in the era of ART, at least in developed countries. Today, the incidence of KS is less than 10% of the incidence reported in 1994⁴. Nonetheless, by presenting this case we would like to emphasize the importance of keeping the possibility of KS in mind even in

HIV-infected patients with high CD4⁺ cell count and on antiretroviral treatment in order not to miss this potentially devastating disease. Our patient's case challenges the common perception of KS as an AIDS-defining illness in patients with normal CD4⁺ cell counts.

Acknowledgments:

We would like to thank the patient for participating in the Zurich Primary HIV Infection Study.

References:

1. Rieder P, Joos B, Scherrer AU, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. *Clin Infect Dis* 2011;53:1271-9.
2. Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. *AIDS* 2013;27:597-605.
3. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *Br J Cancer* 2008;99:800-4.
4. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. *Cancer* 2004;100:2644-54.
5. Daly ML, Fogo A, McDonald C, Morris-Jones R. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm at presentation. *Clin Exp Dermatol* 2013.
6. Crum-Cianflone NF, Hullsiek KH, Ganesan A, et al. Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? *AIDS* 2010;24:2881-3.
7. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 1994;266:1865-9.
8. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. *Clin Infect Dis* 2008;47:1209-15.
9. Sullivan SG, Hirsch HH, Franceschi S, et al. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. *AIDS* 2010;24:2245-52.
10. Beyari MM, Hodgson TA, Cook RD, et al. Multiple human herpesvirus-8 infection. *J Infect Dis* 2003;188:678-89.
11. Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. *HIV Med* 2008;9:336-88.
12. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. *N Engl J Med* 2007;357:1352-3.
13. Bihl F, Berger C, Chisholm JV, 3rd, et al. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. *AIDS* 2009;23:1918-22.
14. Lambert M, Gannage M, Karras A, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. *Blood* 2006;108:3871-80.

Figure 1:




A: Left foot, malleolar. Dark brown patchy lesion measuring 3x5mm




B: Glans penis. Dark brown papule measuring 2x2mm

Figure 2:



A: Hematoxylin-eosin stain. Dermal tumor consisting of spindle cells with irregular vessel lumina formation, plasma cells and erythrocyte extravasates in the tumoral stroma



B: HHV-8 stain. Positive HHV-8 immunochemistry staining in spindle cells.